News & Views

Ripple announced a collaboration and option-to-license agreement with AbbVie to develop next-generation therapies for glaucoma management.

Glaucoma Research Foundation (GRF) will host the 13th Annual Glaucoma 360 New Horizons Forum on February 9th at San Francisco’s historic Westin St. Francis Hotel.

Glaucoma Research Foundation (GRF) President and CEO, Thomas M. Brunner announced the 2024 Annual Gala honorees.

At the 2020 New Horizons Forum, Savas Komban, co-founder and CEO of Smartlens Inc., presented during the “Show Me The Money: Getting to Go in Early Stage Glaucoma Financing” session about their new soft contact lens that would monitor IOP continuously for 24 hours at a time.

Glaucoma Research Foundation (GRF) will host the 12th Annual Glaucoma 360 New Horizons Forum on February 3rd at San Francisco’s iconic Westin St. Francis Hotel.

Glaucoma Research Foundation President and CEO, Thomas M. Brunner announced the 2023 Gala honorees today including Santen Pharmaceutical Co., Ltd. (Santen), Mark A. Latina, MD, and Ted and Melza Barr.

Glaucoma Research Foundation (GRF) President and CEO Thomas M. Brunner announced today that Santen Pharmaceutical Co., Ltd (hereafter, “Santen”), will receive GRF’s highest honor, the Catalyst Award, at the Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco.

New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.

Thurein Htoo, MS, MBA, CEO of Qlaris Bio, Inc. presented at the Glaucoma 360 New Horizons Forum in San Francisco in February 2020 during the session “Show Me the Money—Getting to Go in Early Stage Glaucoma Financing.”

“Tremendous event to meet key leaders in the field and learn from those leading innovation in glaucoma.” — David Esposito, CEO, ONL Therapeutics, Inc.

The 2022 Glaucoma 360 opening Keynote Address, “The Future of Eye Care: Science Fiction to Science Fact” was presented by Ranya Habash, MD.

Glaucoma Research Foundation (GRF) President and CEO, Thomas M. Brunner, announced today that David Calkins, PhD, a leading authority on the neurobiological basis of vision loss in blinding eye disease, will be honored at the Glaucoma 360 Annual Gala on February 10, 2022.

The 2021 Glaucoma 360 opening Keynote Address — “Glaucoma: What predictions came true?” was presented by George A. Cioffi, MD, Edward S. Harkness Chairman and Ophthalmologist-in-Chief of the Department of Ophthalmology, New York-Presbyterian Hospital, Columbia University Medical Center.

New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.

This year’s Glaucoma 360 New Horizons Forum — the 10th annual — took place as a virtual event on January 30, 2021.

The 10th Annual Glaucoma 360 was presented in January 2021 on a global virtual platform.

Dr. Marcellino was a friend and collaborator with leading physicians, scientists, and engineers around the world.